Amgen Prepares to Showcase Innovations at TD Cowen Health Care Conference 2026

Amgen Showcases Leadership in Biotechnology with Upcoming Conference Presentation

Amgen, a prominent player in the biotechnology arena, prepares to take the stage at the 46th Annual TD Cowen Health Care Conference on March 2, 2026. Senior Vice President of Global Marketing and Access, Kave Niksefat, and Senior Vice President of Finance, Justin Claeys, will represent the company during the presentation, scheduled to begin at 1:10 p.m. ET. As Amgen continues to solidify its standing in biopharmaceutical innovation, this conference provides a crucial platform for the company to highlight its advancements and strategic vision in transforming healthcare.

Amgen’s commitment to innovation remains unwavering as the company focuses on developing therapies that address critical health issues, including cancer, cardiovascular diseases, and rare genetic conditions. By leveraging cutting-edge biological research and advanced technology, Amgen aims to create impactful medicines that improve the lives of patients globally. This initiative aligns with Amgen's ethos of patient-centricity and underlines its mission to tackle various health challenges that afflict millions. The forthcoming presentation at the TD Cowen Conference serves as an opportunity for Amgen to showcase its continued dedication to these significant medical needs.

The company's reputation as an industry pioneer is bolstered by its inclusion in the Nasdaq-100 Index® and the Dow Jones Industrial Average®, which reflects its notable market capitalization and influence within the biotechnology sector. Amgen’s advancements have not only garnered recognition for innovation from notable publications like Fast Company and Forbes but have also established a workplace culture that prioritizes creativity and progress. By inviting stakeholders to engage via a live webcast, Amgen ensures transparency and accessibility, reinforcing its commitment to maintaining stakeholder relationships in an ever-evolving industry landscape.

In tandem with their upcoming conference presentation, Amgen continues to encourage stakeholders and the public to stay informed about their latest developments. The company maintains an active online presence through its website and social media channels, providing ongoing updates and engaging with patients, healthcare professionals, and investors alike. Media and investor inquiries can be directed to the contact information provided, showcasing Amgen’s commitment to open communication and transparency in their operations and innovations in biotechnology.